RecruitingPhase 2NCT04939623
Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
Studying Opsoclonus-myoclonus syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Calgary
- Principal Investigator
- Lori Montgomery, MDUniversity of Calgary
- Intervention
- Probenecid(drug)
- Enrollment
- 40 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Richmond Road Diagnostic and Treatment Centre, Calgary, Alberta, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04939623 on ClinicalTrials.govOther trials for Opsoclonus-myoclonus syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07485517Deep Versus Moderate Neuromuscular BlockingMenoufia University
- ACTIVE NOT RECRUITINGNANCT07419815IV Lidocaine Infusion Versus Placebo for Pain Control in Staging Laparoscopy CasesShaukat Khanum Memorial Cancer Hospital & Research Centre
- RECRUITINGNANCT07473648Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure TherapyThe Second Hospital of Anhui Medical University
- ACTIVE NOT RECRUITINGNCT07144410Pain Control and Side Effects in Cesarean Section Anesthesia: Comparison of Intrathecal Morphine and FentanylUniversity of Oradea
- RECRUITINGPHASE2NCT07036406Comparing Traditional Semantic Feature Analysis (tSFA) and Semantic Feature Analysis + Metacognitive Strategy Training (SFA+MST)Teachers College, Columbia University
- RECRUITINGPHASE3NCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Novartis Pharmaceuticals
- RECRUITINGPHASE4NCT06797973Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean SectionAnne Juul Wikkelsø
- RECRUITINGPHASE3NCT06847724Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisSandoz